GENERALIZED MYASTHENIA GRAVIS

This study tests a drug called inebilizumab in 15 children aged 2 to 17 who have generalized myasthenia gravis, a disease that causes muscle weakness. The goal is to see how the drug moves through the body, how it affects immune cells, and whether it is safe. While the drug may h…

This study tests whether the drug ravulizumab can improve daily activities in people with early-stage generalized myasthenia gravis who have a specific antibody (AChR+). About 40 participants will receive treatment and be followed for 50 weeks. The goal is to see if starting trea…

This study tests a new treatment called KYV-101, made from a patient's own immune cells, against standard drugs for generalized myasthenia gravis. The goal is to see if this one-time cell therapy can better control symptoms like muscle weakness and fatigue. About 66 adults who ha…

This study looks at whether people with generalized myasthenia gravis (gMG) who are already taking the drug ravulizumab can safely reduce or stop their oral steroids. About 75 adults will follow a step-by-step steroid-tapering schedule. The goal is to lower steroid doses without …

This study tests a drug called rozanolixizumab in 12 children aged 2 to 17 with moderate to severe generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug is safe and helps control symptoms. Participants receive the drug as a shot un…

This study is testing a drug called zilucoplan in children aged 2 to 17 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug works in the body, how safe it is, and if it helps control the disease. Only 8 children will ta…

This study tests a new oral form of cladribine to see if it improves daily activities and muscle strength in people with generalized myasthenia gravis, a condition causing muscle weakness. About 264 adults will receive either the drug or a placebo, and researchers will track chan…

This study tests an investigational drug called IMVT-1402 in people with mild to severe generalized myasthenia gravis, a condition that causes muscle weakness. About 231 adults will receive either the drug or a placebo to see if it improves daily activities and muscle strength. T…

This study tests a drug called gefurulimab in 12 children aged 6 to 18 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see how the drug moves through the body, how well it works, and if it is safe. Participants will receive the drug…

This study is testing a new medicine called cizutamig in people with generalized myasthenia gravis (gMG), a condition that causes muscle weakness. The main goal is to check if the drug is safe and how the body processes it. About 44 adults with moderate to severe symptoms who hav…

This study tests an oral drug called iptacopan in people with generalized myasthenia gravis (gMG), a condition causing muscle weakness. About 146 adults with a specific antibody (AChR+) will receive either iptacopan or a placebo for 6 months, alongside their usual treatments. The…

This study is testing different drug combinations to find safer and more effective treatments for people with myasthenia gravis, a condition that causes muscle weakness. About 70 adults with generalized MG will try either a new drug alone or added to their current treatment. The …

This study tests a drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to find the right dose and check for side effects. Participants receive injections and are monitored for up to 14 weeks.

This study tests a new drug, B007, in 104 people with generalized myasthenia gravis, a condition causing muscle weakness. Participants will receive either B007 or a placebo, and researchers will measure improvements in daily activities over time. The goal is to see if B007 can be…

This study tests an investigational drug called efgartigimod in children aged 2 to 17 with generalized myasthenia gravis, a condition that causes muscle weakness. The trial aims to understand how the drug works in young bodies, its safety, and its effects. Up to 12 participants w…

This study tests a new drug called remibrutinib against a placebo in 180 adults with generalized myasthenia gravis, a condition causing muscle weakness. Participants must already be on standard treatments. The goal is to see if the drug improves daily activities and muscle streng…

This study tests whether adding empasiprubart to the standard treatment efgartigimod can further improve symptoms in people with a specific type of generalized myasthenia gravis (gMG). About 70 adults who still have partial symptoms despite efgartigimod will receive the combinati…

This study tests if telitacicept can help people with generalized myasthenia gravis, a condition causing muscle weakness. About 180 adults will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug improves daily activities and muscle strength.

This early-stage trial tests a new treatment called YTB323, a CAR-T cell therapy, for people with generalized myasthenia gravis that hasn't improved with standard treatments. The study will enroll 15 participants to check if the therapy is safe and how well it works. The goal is …

This study is a long-term registry that will follow about 500 people with generalized myasthenia gravis (gMG) who are taking or have taken C5 inhibitor drugs like Soliris or Ultomiris. Researchers will collect information on safety and how well the drugs help with daily activitie…